Physician's Weekly

JULY 1, 2025

The annual meeting of the American Diabetes Association was held this year from June 20 to 23 in Chicago, drawing more than 15,000 participants, including clinicians, academicians, allied health professionals, and others interested in diabetes. ” The study was funded by MannKind, the manufacturer of Afrezza. .

Diabetes 52

Diabetes Patient-Centered Management Individual 52

Plum Health

AUGUST 30, 2024

Managing diabetes—especially as you get older—can be challenging physically, emotionally, and financially. If you’re living with Type 2 diabetes, you’ve probably heard of Ozempic, Wegovy (semaglutide), Mounjaro or Zepbound (tirzepatide). Save with patient assistance programs.

Primary Care 52

Primary Care Insurance Diabetes Manufacturing 52

FDA Law

JULY 22, 2021

Schlanger — Maine and Nevada previously enacted laws requiring drug manufacturers to report information about the pricing of their products. Both states’ new requirements will become effective in October 2021 and should be considered as manufacturers prepare for state drug price transparency reporting in 2022.

Manufacturing 52

Manufacturing Asthma Diabetes Family 52

GeriPal

JUNE 20, 2024

Incontinence and avoiding issues can present in an older individual, in some cases, just like they do a younger person. Biological aging or physiological aging varies from individual to individual. How do you think about this from a clinical perspective when you’re seeing individuals in your office? Everybody ages.

IT 120

IT Patient-Centered Patients Clinic 120

FDA Law

SEPTEMBER 8, 2022

As it stands, the rule allows insurers and pharmacy benefit managers (PBMs) to broadly use copay accumulator programs, which have long been criticized by patient advocacy groups as padding insurers’ pockets while leaving patients high and dry. These prohibitions are often referred to as copay accumulator adjustment programs.

Insurance 83

Insurance Patients Manufacturing Patient-Centered 83

FDA Law

SEPTEMBER 13, 2021

A final OIG rule to change the structure of manufacturer rebates to Medicare Part D and Medicaid Managed Care plans and their PBMs is enmeshed in litigation and is likely to be at least postponed until 2026 (see our post ), and perhaps prevented from implementation altogether, by Congressional mandate.

Manufacturing 98

Manufacturing Supply Chain Patient-Centered Utilities 98